{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:34:27Z","timestamp":1790652867502,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Our study examines modification patents across multiple New Drug Applications (NDAs), employed by pharmaceutical companies to extend patent protections. Ours is the only comprehensive study of modification patents by Active Pharmaceutical Ingredient (API) across multiple NDAs, the approach of current regulatory initiatives, investigating how these patents extend drug protections and impede generic entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examine 1028 modification patents, categorizing them as chemical variations, formulation changes, treatment methods, or device\/agent. We tabulated additional granted protection time, correlations with new NDAs, and litigation from potential generics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On average, 5 modification patents protected each drug, extending granted protection periods by 10.9 years. Examining market outcomes for the 199 drugs with generics approved by August 2025, or whose primary patents had expired by then, modification patents provided a median of 2.3 years' median effective additional protection time before generic entry. Eighty-nine percent of drugs' protection periods were extended by modification patenting in some dimension. Fifty-eight percent had a modification patent associated with a new NDA, and 70% had at least 1 modification patent in Paragraph IV-related litigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest we reconsider societal resources dedicated to modification patenting, generally and during clinical decision-making. Hope for regulatory and legislative reform lies in a \u201cone-and-done\u201d policy and restricting certain patent types.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/haschl\/qxag123","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:40:26Z","timestamp":1779277226000},"source":"Crossref","is-referenced-by-count":1,"title":["Modification patents across multiple NDAs in pharmaceutical protections"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-134X","authenticated-orcid":false,"given":"Robin","family":"Feldman","sequence":"first","affiliation":[{"name":"Center for Innovation (C4i), University of California Law, SanFrancisco , San Francisco, CA 94102 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5552-4537","authenticated-orcid":false,"given":"Ramy","family":"Alsaffar","sequence":"additional","affiliation":[{"name":"Center for Innovation (C4i), University of California Law, SanFrancisco , San Francisco, CA 94102 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8815-1853","authenticated-orcid":false,"given":"Tanziuzzaman","family":"Sakib","sequence":"additional","affiliation":[{"name":"Center for Innovation (C4i), University of California Law, SanFrancisco , San Francisco, CA 94102 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026061611422900000_qxag123-B1","first-page":"788","article-title":"Solutions still searching for a problem: a call for relevant data to support \u201cevergreening\u201d allegations","volume":"33","author":"Leitzan","year":"2023","journal-title":"Fordham Intell. Prop. Media @ Ent L J"},{"issue":"12","key":"2026061611422900000_qxag123-B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049470","article-title":"Polymorphs and prodrugs and salts (Oh My!): an empirical analysis of \u201csecondary\u201d pharmaceutical patents","volume":"7","author":"Kapczynski","year":"2012","journal-title":"PLoS One"},{"key":"2026061611422900000_qxag123-B3","author":"Correa"},{"key":"2026061611422900000_qxag123-B4","author":"European Commission"},{"issue":"3","key":"2026061611422900000_qxag123-B5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/jlb\/lsy022","article-title":"May your drug price be evergreen","volume":"5","author":"Feldman","year":"2018","journal-title":"J Law Biosci"},{"key":"2026061611422900000_qxag123-B6","author":"Armstrong"},{"issue":"3","key":"2026061611422900000_qxag123-B7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.18060\/4806.1153","article-title":"In defense of secondary pharmaceutical patents: a response to the UN's guidelines for pharmaceutical patent examination","volume":"50","author":"Holman","year":"2017","journal-title":"Ind L Rev"},{"issue":"10","key":"2026061611422900000_qxag123-B8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nbt.1993","article-title":"Evergreening: a common practice to protect new drugs","volume":"29","author":"Gaudry","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2026061611422900000_qxag123-B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148939","article-title":"Is patent \u201cevergreening\u201d restricting access to medicine\/device combination products?","volume":"11","author":"Beall","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"2026061611422900000_qxag123-B10","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1377\/hlthaff.2012.0107","article-title":"Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades","volume":"31","author":"Amin","year":"2012","journal-title":"Health Aff (Millwood)"},{"key":"2026061611422900000_qxag123-B11"},{"key":"2026061611422900000_qxag123-B12","first-page":"8","article-title":"Medicare drug price negotiation program: initial memorandum, implementation of sections 1191\u20131198 of the Social Security Act for initial price applicability year 2026, and solicitation of comments","volume":"1-91","author":"Sheshamani","year":"2023","journal-title":"Centers for Medicare and Medicaid"},{"key":"2026061611422900000_qxag123-B13","author":"Sachs"},{"key":"2026061611422900000_qxag123-B14"},{"key":"2026061611422900000_qxag123-B15","first-page":"517","article-title":"Valuing medical innovation","volume":"75","author":"Hemel","year":"2023","journal-title":"Stan L Rev"},{"key":"2026061611422900000_qxag123-B16","author":"U.S. Food & Drug Administration"},{"key":"2026061611422900000_qxag123-B17","author":"Clarivate"},{"key":"2026061611422900000_qxag123-B18","author":"U.S. Food & Drug Administration"},{"key":"2026061611422900000_qxag123-B19","author":"U.S. Patent and Trademark Office"},{"key":"2026061611422900000_qxag123-B20","author":"National Institute of Health"},{"key":"2026061611422900000_qxag123-B21","author":"Bloomberg"},{"key":"2026061611422900000_qxag123-B22","author":"U.S. Food & Drug Administration"},{"key":"2026061611422900000_qxag123-B23","author":"Evergreen Drug Patent Database"},{"key":"2026061611422900000_qxag123-B24","author":"UCL Therapeutic Innovation Networks"},{"key":"2026061611422900000_qxag123-B25","first-page":"79","article-title":"Why pharmaceutical patent thickets are unique","volume":"79","author":"Carrier","year":"2024","journal-title":"Tex Int Prop J"},{"key":"2026061611422900000_qxag123-B26","author":"Federal Trade Commission"},{"key":"2026061611422900000_qxag123-B27","author":"Haucap"},{"key":"2026061611422900000_qxag123-B28","first-page":"2","article-title":"Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices","volume":"1-9","author":"Conrad","year":"2019","journal-title":"US Food Drug Admin"},{"key":"2026061611422900000_qxag123-B29"},{"key":"2026061611422900000_qxag123-B30","author":"European Union"},{"key":"2026061611422900000_qxag123-B31","author":"Cohen"},{"key":"2026061611422900000_qxag123-B32"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxag123\/68350206\/qxag123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/6\/qxag123\/68350206\/qxag123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/6\/qxag123\/68350206\/qxag123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:42:43Z","timestamp":1781624563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxag123\/8688695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxag123","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,21]]},"article-number":"qxag123"}}